Translational Transplant Research Center, Tisch Cancer Institute, Precision Immunology Institute, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Translational Transplant Research Center, Tisch Cancer Institute, Precision Immunology Institute, Tisch Cancer Institute and Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Transplant Cell Ther. 2022 Aug;28(8):472.e1-472.e11. doi: 10.1016/j.jtct.2022.05.031. Epub 2022 May 25.
Conditioning regimens used for hematopoietic stem cell transplantation (HCT) can escalate the severity of acute T cell-mediated graft-versus-host disease (GVHD) by disrupting gastrointestinal integrity and initiating lipopolysaccharide (LPS)-dependent innate immune cell activation. Activation of the complement cascade has been associated with murine GVHD, and previous work has shown that alternative pathway complement activation can amplify T cell immunity. Whether and how mannan-binding lectin (MBL), a component of the complement system that binds mannose as well as oligosaccharide components of LPS and lipoteichoic acid, affects GVHD is unknown. In this study, we tested the hypothesis that MBL modulates murine GVHD and examined the mechanisms by which it does so. We adoptively transferred C3.SW bone marrow (BM) cells ± T cells into irradiated wild type (WT) or MBL-deficient C57Bl/6 (B6) recipients with or without inhibiting MBL-initiated complement activation using C1-esterase inhibitor (C1-INH). We analyzed the clinical severity of disease expression and analyzed intestinal gene and cell infiltration. In vitro studies assessed MBL expression on antigen-presenting cells (APCs) and compared LPS-induced responses of WT and MBL-deficient APCs. MBL-deficient recipients of donor BM ± T cells exhibited significantly less weight loss over the first 2 weeks post-transplantation weeks compared with B6 controls (P < .05), with similar donor engraftment in the 2 groups. In recipients of C3.SW BM + T cells, the clinical expression of GVHD was less severe (P < .05) and overall survival was better (P < .05) in MBL-deficient mice compared with WT mice. On day-7 post-transplantation, analyses showed that the MBL-deficient recipients exhibited less intestinal IL1b, IL17, and IL12 p40 gene expression (P < .05 for each) and fewer infiltrating intestinal CD11c, CD11b, and F4/80 cells and TCRβ, CD4, CD4IL17, and CD8 T cells (P < .05 for each). Ovalbumin or allogeneic cell immunizations induced equivalent T cell responses in MBL-deficient and WT mice, demonstrating that MBL-deficiency does not directly impact T cell immunity in the absence of irradiation conditioning. Administration of C1-INH did not alter the clinical expression of GVHD in preconditioned WT B6 recipients, suggesting that MBL amplifies clinical expression of GVHD via a complement-independent mechanism. WT, but not MBL-deficient, APCs express MBL on their surfaces. LPS-stimulated APCs from MBL-deficient mice produced less proinflammatory cytokines (P < .05) and induced weaker alloreactive T cell responses (P < .05) compared with WT APCs. Together, our data show that MBL modulates murine GVHD, likely by amplifying complement-independent, LPS-initiated gastrointestinal inflammation. The results suggest that devising strategies to block LPS/MBL ligation on APCs has the potential to reduce the clinical expression of GVHD.
用于造血干细胞移植(HCT)的调理方案可通过破坏胃肠道完整性和引发脂多糖(LPS)依赖性固有免疫细胞激活来加重急性 T 细胞介导的移植物抗宿主病(GVHD)的严重程度。补体级联的激活与小鼠 GVHD 有关,先前的研究表明替代途径补体激活可以增强 T 细胞免疫。甘露聚糖结合凝集素(MBL)是补体系统的一部分,可结合甘露糖以及 LPS 和脂磷壁酸的寡糖成分,它是否以及如何影响 GVHD 尚不清楚。在这项研究中,我们检验了 MBL 调节小鼠 GVHD 的假设,并研究了其作用机制。我们将 C3.SW 骨髓(BM)细胞±T 细胞过继转移到照射的野生型(WT)或 MBL 缺陷型 C57Bl/6(B6)受者中,并用 C1-酯酶抑制剂(C1-INH)抑制 MBL 起始的补体激活。我们分析了疾病表达的临床严重程度,并分析了肠道基因和细胞浸润。体外研究评估了抗原呈递细胞(APC)上的 MBL 表达,并比较了 WT 和 MBL 缺陷型 APC 对 LPS 的反应。与 B6 对照相比,接受供体 BM±T 细胞的 MBL 缺陷型受者在移植后前 2 周体重减轻明显减少(P <.05),两组供体植入相似。在接受 C3.SW BM + T 细胞的受者中,与 WT 小鼠相比,MBL 缺陷型小鼠的 GVHD 临床表型较轻(P <.05),总生存率更高(P <.05)。在移植后第 7 天,分析显示 MBL 缺陷型受者的肠道 IL1b、IL17 和 IL12 p40 基因表达减少(每项 P <.05),肠道浸润的 CD11c、CD11b 和 F4/80 细胞以及 TCRβ、CD4、CD4IL17 和 CD8 T 细胞减少(每项 P <.05)。卵清蛋白或同种异体细胞免疫接种在 MBL 缺陷型和 WT 小鼠中诱导了等效的 T 细胞反应,表明 MBL 缺陷型在没有辐照调理的情况下不会直接影响 T 细胞免疫。在预处理的 WT B6 受者中给予 C1-INH 并未改变 GVHD 的临床表型,这表明 MBL 通过补体非依赖性机制放大 GVHD 的临床表型。WT,但不是 MBL 缺陷型,APC 表面表达 MBL。与 WT APC 相比,来自 MBL 缺陷型小鼠的 LPS 刺激的 APC 产生更少的促炎细胞因子(P <.05)并诱导较弱的同种反应性 T 细胞反应(P <.05)。总的来说,我们的数据表明 MBL 调节小鼠 GVHD,可能通过放大补体非依赖性、LPS 起始的胃肠道炎症来实现。结果表明,设计阻断 LPS/MBL 与 APC 结合的策略有可能降低 GVHD 的临床表型。